Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 11/20 | 0.66 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.66 |
| ▸ | AR | P10275 | 1/20 | 0.66 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.66 |
| ▸ | PTPN2 | P17706 | 3/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.46 |
| ▸ | PTPN5 | P54829 | 3/20 | 0.46 |
| ▸ | HSPD1 | P10809 | 2/20 | 0.46 |
| ▸ | HSPE1 | P61604 | 2/20 | 0.46 |
| ▸ | PLAU | P00749 | 1/20 | 0.44 |
| ▸ | PLAT | P00750 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | IDH2 | P48735 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | RXRA | P19793 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6716620 | 0.86 | NR3C1 (0.53) | PGRNR3C1ARESR2PTPN2 | |
| SCHEMBL6718287 | 0.86 | FFAR1 (0.47) | PGRNR3C1ARESR2MAPT | |
| SCHEMBL7124579 | 0.86 | KDM1A (0.48) | PGRNR3C1ARESR2PTPN2 | |
| SCHEMBL6724650 | 0.86 | PTPN2 (0.48) | PGRNR3C1ARESR2PTPN2 | |
| SCHEMBL6724676 | 0.85 | PGR (0.62) | PGRPLAU | |
| SCHEMBL6776203 | 0.83 | FFAR1 (0.60) | PGRARLMNA | |
| SCHEMBL6720526 | 0.82 | THRB (0.52) | PGRNR3C1ARESR2PTPN2 | |
| SCHEMBL6715048 | 0.80 | PGR (0.41) | PGRNR3C1ARESR2 | |
| SCHEMBL6714954 | 0.80 | THRB (0.50) | PGRNR3C1ARESR2PTPN2 | |
| SCHEMBL6717978 | 0.79 | THRB (0.49) | PGRNR3C1ARESR2PTPN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6818651-B2 | ANTIINFLAMMATORY, ANTIASTHMATIC, SKIN, AND AUTOIMMUNE DISORDERS; CROHN*S DISEASE, ULCERATIVE COLITIS, CONJUCTIVITIS, MULTIPLE SCLEROSIS, AND RHEUMATOID ARTHRITIS; CHRONIC OBSTRUCTIVE PULMONARY DISEASE | ALTANA PHARMA AG (DE) | 2004-11-16 | — | — | US | disclosed |
| US-20040044212-A1 | (Dihydro) Isoquinoline derivatives as phosphodiesterase inhibitors | ALTANA PHARMA AG (DE) | 2004-03-04 | — | — | US | disclosed |
| EP-1337515-A1 | (DIHYDRO)ISOQUINOLINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 2003-08-27 | — | — | EP | disclosed |
| WO-2002040450-A1 | (DIHYDRO)ISOQUINOLINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS | ALTANA PHARMA AG (DE) | 2002-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040044212-A1 | (Dihydro) Isoquinoline derivatives as phosphodiesterase inhibitors | PDE7B, PDE3B, PDE3A | PGR 3452/4885NR3C1 2751/4885AR 108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.